@article{283697a1f01a41b7a301553c29ec2dea,
title = "Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies",
abstract = "Homozygous familial hypercholesterolaemia (FH) causes severe premature coronary artery disease because of very high levels of low density lipoprotein (LDL)-cholesterol. Standard lipid-lowering drugs and LDL-apheresis may not be sufficiently effective. Liver transplantation replaces defective LDL receptors and vastly improves the lipid profile, and we present the first report of an Australian adult to receive this treatment. Emerging drug treatments for FH may be alternatives to LDL-apheresis and transplantation, but long-term safety and efficacy data are lacking for all of these options. ",
keywords = "acetylsalicylic acid, atenolol, atorvastatin, cholesterol, ezetimibe, fenofibrate, isosorbide mononitrate, low density lipoprotein cholesterol, low density lipoprotein receptor, mycophenolic acid 2 morpholinoethyl ester, prednisolone, rosuvastatin, tacrolimus, warfarin, antilipemic agent, azetidine derivative, heptanoic acid derivative, low density lipoprotein, pyrrole derivative, angina pectoris, angiocardiography, aorta stenosis, aorta valve replacement, apheresis, article, bypass surgery, cadaver donor, case report, cholesterol blood level, clinical effectiveness, coronary artery bypass graft, coronary artery disease, drug dose increase, exon, familial hypercholesterolemia, gene, genetic variability, heterozygosity, homozygosity, human, human tissue, liver biopsy, liver function test, liver graft rejection, liver transplantation, low density lipoprotein receptor gene, male, mitral valve replacement, patient safety, postoperative complication, priority journal, pulmonary valve replacement, Ross procedure, stress echocardiography, xanthoma, adult, blood, consanguinity, Coronary Disease, deficiency, diet therapy, drug combination, genetics, Heart Valve Diseases, heart valve replacement, homozygote, Hyperlipoproteinemia Type II, multimodality cancer therapy, Adult, Azetidines, Blood Component Removal, Cholesterol, LDL, Combined Modality Therapy, Consanguinity, Coronary Artery Bypass, Drug Therapy, Combination, Fenofibrate, Heart Valve Prosthesis Implantation, Heptanoic Acids, Homozygote, Humans, Hypolipidemic Agents, Lipoproteins, LDL, Liver Transplantation, Male, Pyrroles, Receptors, LDL",
author = "M Page and Ekinci, {E. I.} and Jones, {R. M.} and Angus, {P. W.} and Gow, {P. J.} and O'Brien, {R. C.}",
year = "2014",
month = jun
doi = "10.1111/imj.12444",
language = "English",
volume = "44",
pages = "601--604",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "6",
}